Effect of 4-Aminopyridine on Genioglossus Muscle Activity during Sleep in Healthy Adults
Data
2017
Autores
de Melo, Camila M. 
Mostrar mais
Tipo
Artigo
Título da Revista
ISSN da Revista
Título de Volume
Resumo
Rationale: The reduction in upper airway muscle activity from wakefulness to sleep plays a key role in the development of obstructive sleep apnea. Potassium (K+) channels have been recently identified as the downstream mechanisms through which hypoglossal motoneuron membrane excitability is reduced both in non-rapid eye movement (NREM) sleep and REM sleep. In animal models, the administration of 4-aminopyridine (4-AP), a voltage-gated K+ channel blocker, increased genioglossus activity during wakefulness and across all sleep stages. Objectives: We tested the hypothesis that administration of a single dose of 4-AP 10 mg extended release would increase genioglossus activity (electromyography of the genioglossus muscle [EMG(GG)]) during wakefulness and sleep, and thereby decrease pharyngeal collapsibility. Methods: We performed a randomized controlled crossover proof-of- concept trial in 10 healthy participants. Participants received active treatment or placebo in randomized order 3 hours before bedtime in the physiology laboratory. Results: EMG(GG) during wakefulness and NREM sleep and upper airway collapsibility measured during NREM sleep were unchanged between placebo and 4-AP nights. Tonic but not phasic EMGGG during REM sleep was higher on the 4-AP night when measured as a percentage of maximal voluntary activation (median [interquartile range] 0.3 [0.5] on placebo vs. 0.8 [1.9] %(max) on 4 AP
P = 0.04), but not when measured in mu V or as a percentage of wakefulness value. Conclusions: A single dose of 4-AP 10 mg extended release showed only a small increase in tonic EMG(GG) during REM sleep in this group of healthy subjects. We speculate that a higher dose of 4-AP may further increase EMG(GG). However, given the potentially severe, dose-related adverse effects of this drug, including seizures, the administration of 4-AP does not appear to be an effective strategy to increase genioglossus activity during sleep in humans.
P = 0.04), but not when measured in mu V or as a percentage of wakefulness value. Conclusions: A single dose of 4-AP 10 mg extended release showed only a small increase in tonic EMG(GG) during REM sleep in this group of healthy subjects. We speculate that a higher dose of 4-AP may further increase EMG(GG). However, given the potentially severe, dose-related adverse effects of this drug, including seizures, the administration of 4-AP does not appear to be an effective strategy to increase genioglossus activity during sleep in humans.
Descrição
Citação
Annals Of The American Thoracic Society. New York, v. 14, n. 7, p. 1177-1183, 2017.